CV Sciences leverages a portfolio of science-backed CBD products including gummies, softgels, topicals, and pet products sold through multiple channels—retail stores, distributors, e-commerce, and direct-to-consumer. The company has established significant retail distribution (8,400+ locations as of end 2021) and positions itself on clinical research validation and GMP compliance, differentiating from competitors in the fragmented hemp supplement space.
Cyborg Score Rationale
CV Sciences holds a recognized market position in CBD consumer products with multi-channel distribution and science-backed positioning. However, the company faces headwinds from declining revenue (FY2021: $20.0M vs FY2020: $24.4M), compressed margins (43.0% in 2021 vs 45.1% in 2020), and limited liquidity ($1.4M cash at end 2021). OTC trading status and lack of recent public financials (post-2021) create visibility challenges.
Top Insights
PlusCBD ranks among top-selling hemp-derived CBD brands by SPINS market data, indicating established consumer recognition and retail traction
Dual business model (consumer products + pharmaceutical development) positions company for potential upside if CBD therapeutics advance, though drug development segment contribution remains unclear
Revenue declined 18% from FY2020 ($24.4M) to FY2021 ($20.0M), signaling competitive or market headwinds in consumer CBD segment despite retail distribution growth
Low cash position ($1.4M end-2021) and reliance on convertible debt and preferred stock issuances suggest capital constraints; recent financials (2022+) not publicly available
Named Competitors
Charlotte's Web — Hemp-derived CBD consumer wellness products
Elixinol — Hemp extract and CBD products globally distributed
cbdMD — Broad-spectrum and THC-free CBD products
Recent Developments
(Q3 2021) Launched PlusCBD Reserve full spectrum hemp extract line
(Q4 2021) Announced new distribution agreement with GNC
(Q1 2022) Launched PlusCBD pain relief topicals and Relief softgels
(Q1 2022) Entered securities purchase agreements for convertible notes and preferred stock/warrants
Open the full interactive CV Sciences, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.